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BSTRACT
 
Background
 
Treatment of stenosis in saphenous-
vein grafts after coronary-artery bypass surgery is a
difficult challenge. The purpose of this study was to
compare the effects of stent placement with those of
balloon angioplasty on clinical and angiographic out-
comes in patients with obstructive disease of saphe-
nous-vein grafts.
 
Methods
 
A total of 220 patients with new lesions
in aortocoronary–venous bypass grafts were random-
ly assigned to placement of Palmaz–Schatz stents or
standard balloon angioplasty. Coronary angiography
was performed during the index procedure and six
months later.
 
Results
 
As compared with the patients assigned
to angioplasty, those assigned to stenting had a high-
er rate of procedural efficacy, defined as a reduction
in stenosis to less than 50 percent of the vessel
diameter without a major cardiac complication (92
percent vs. 69 percent, P
 

 
0.001), but they had more
frequent hemorrhagic complications (17 percent vs.
5 percent, P
 

 
0.01). Patients in the stent group had a
larger mean (
 

 
SD) increase in luminal diameter
immediately after the procedure (1.92
 

 
0.30 mm, as
compared with 1.21
 

 
0.37 mm in the angioplasty
group; P
 

 
0.001) and a greater mean net gain in lumi-
nal diameter at six months (0.85
 

 
0.96 vs. 0.54
 

 
0.91
mm, P
 

 
0.002). Restenosis occurred in 37 percent of
the patients in the stent group and in 46 percent of
the patients in the angioplasty group (P
 

 
0.24). The
outcome in terms of freedom from death, myo-
cardial infarction, repeated bypass surgery, or revas-
cularization of the target lesion was significantly
better in the stent group (73 percent vs. 58 percent,
P
 

 
0.03).
 
Conclusions
 
As compared with balloon angio-
plasty, stenting of selected venous bypass-graft le-
sions resulted in superior procedural outcomes, a
larger gain in luminal diameter, and a reduction in
major cardiac events. However, there was no sig-
nificant benefit in the rate of angiographic resteno-
sis, which was the primary end point of the study.
(N Engl J Med 1997;337:740-7.)
 
©1997, Massachusetts Medical Society.
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HE treatment of patients with obstructive
disease of coronary-artery bypass grafts pos-
es a challenge of increasing magnitude as
the population of patients who have under-
gone bypass surgery continues to grow. Within a
decade after surgery, half of all saphenous-vein bypass
grafts have severe atherosclerotic disease.
 
1-7
 
 Manage-
ment of graft disease is problematic, since repeated
surgery entails substantial risk and the results of con-
ventional angioplasty have been disappointing.
 
8-12 
 
As
compared with angioplasty in native coronary arter-
ies, balloon dilation of vein grafts is associated with
increased rates of procedural complications and re-
stenosis.
 
12-16
 
 Previous randomized trials of stent im-
plantation, as compared with balloon angioplasty,
have shown superior outcomes in native vessels, and
observational reports have suggested favorable results
in diseased vein grafts.
 
17-22
 
 Accordingly, we conduct-
ed a prospective, randomized trial to compare stent
implantation with balloon angioplasty for the treat-
ment of obstructive disease of venous bypass grafts.
 
METHODS
 
Twelve clinical centers with experience with the implantation
of Palmaz–Schatz stents participated in the trial (see the Appen-
dix). The study protocol was approved by the institutional review
board at each site.
 
Selection of Patients
 
The study population consisted of patients with new lesions in
aortocoronary venous bypass grafts who had angina pectoris, ob-
T
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jective evidence of myocardial ischemia, or both. Angiographic
entry criteria included stenosis of 60 percent or more of the lu-
minal diameter in vessels from 3.0 to 5.0 mm in diameter. Exclu-
sion criteria were myocardial infarction within the previous seven
days; a contraindication to therapy with aspirin, dipyridamole, or
warfarin; an ejection fraction of less than 25 percent; diffuse dis-
ease that would require more than two stents; evidence of throm-
bus; and outflow obstruction of the graft due to distal anastomotic
stenosis or poor runoff in the recipient native vessel. After giving
informed consent, patients were randomly assigned to either an-
gioplasty or stent placement.
 
Protocols
 
The stent used in this trial was the 15-mm-long Palmaz–Schatz
coronary stent (Johnson & Johnson Interventional Systems, War-
ren, N.J.).
 
23-25
 
 Patients assigned to stent placement received aspi-
rin (325 mg daily) and dipyridamole (75 mg three times per day),
beginning at least 24 hours before the procedure. During the
procedure, patients received intravenous dextran 40 and heparin
to maintain an activated clotting time of more than 300 seconds.
Warfarin therapy was begun on the day of the procedure, and hep-
arin therapy was continued until a therapeutic prothrombin time
(international normalized ratio, 2.0 to 3.5) was achieved. Dipyrid-
amole and warfarin were continued for one month, and aspirin
indefinitely.
Angioplasty was performed with use of conventional balloon
catheters. Patients in whom angioplasty was successful received
aspirin (325 mg daily) indefinitely. Crossover to stent placement
was permitted as a bailout procedure in the event of abrupt or
threatened vessel closure. Patients assigned to the angioplasty group
who required stent placement as a bailout procedure received war-
farin and dipyridamole for one month in addition to aspirin.
 
Follow-up
 
Patients were evaluated clinically one, three, and six months
after the procedure. Coronary angiography was repeated at six
months. Angiography was performed earlier if there were recur-
rent symptoms. However, if restenosis was not found during re-
peated angiography performed within four months of the proce-
dure, angiography was repeated at six months.
 
Angiographic Analysis
 
Angiography was performed in orthogonal views at base line, af-
ter the intervention, and at six months. Quantitative coronary anal-
ysis was performed at the core angiographic laboratory at Jefferson
Medical College with use of a validated edge-detection algori-
thm.
 
18,24-28
 
 The diameters of the normal-appearing segments prox-
imal and distal to the lesion were averaged to determine the refer-
ence vessel diameter. The minimal luminal diameter, reference
diameter, and degree of stenosis as a percentage of the vessel diam-
eter were calculated as mean values from orthogonal projections.
 
End Points
 
The primary angiographic end point was restenosis, defined as
stenosis of 50 percent or more of the luminal diameter at follow-
up. When multiple lesions were treated, restenosis was considered
present in a patient if any lesion had restenosis. Secondary angio-
graphic end points included the rate of procedural success and
the change in the minimal luminal diameter from the base-line
value immediately after the procedure and at six months. Proce-
dural success was defined as a reduction in the degree of stenosis
to less than 50 percent, as assessed by quantitative angiography.
Procedural efficacy was also assessed as an initial outcome; this
combined angiographic and clinical end point was intended to re-
flect the overall predictability of the planned intervention. Proce-
dural efficacy was defined as angiographic success with the as-
signed therapy, without crossover to the alternative therapy, and
the absence of in-hospital complications.
The principal clinical end point was a composite outcome de-
fined as the occurrence of death, myocardial infarction, repeated
bypass surgery, or revascularization of the target lesion. Myocar-
dial infarction was defined as the presence of new Q waves lasting
0.04 second or more or an elevation of the serum creatine kinase
level to three times the upper limit of normal with an elevated MB
fraction (measured 6, 12, and 24 hours after the procedure). Sec-
ondary clinical outcomes included the duration of hospitalization
and the frequency of bleeding and peripheral vascular compli-
cations.
 
Statistical Analysis
 
The target sample size of 210 patients was based on the as-
sumption that the rate of restenosis in vein-graft lesions in the an-
gioplasty group would be 50 percent or more and that the rate
of restenosis in stented vessels would be less than 25 percent.
 
20-22
 
Allowing for a procedural failure rate of 10 percent and an angio-
graphic-restudy rate of 80 percent, the enrollment of 210 patients
would yield more than 150 patients with angiographic follow-up
and give the study a statistical power of 0.90 and an alpha level
of 0.05.
Data were recorded prospectively and forwarded to the data-
coordinating center. Case-report forms and charts were indepen-
dently audited by research monitors. Adverse events were re-
viewed in blinded fashion by the steering committee.
Outcomes were analyzed according to the intention-to-treat
principle. Categorical data were assessed by the chi-square or Fish-
er’s exact test. Rates of clinical events in the treatment groups at
6 months (follow-up window, 120 to 240 days) were compared
with use of the log-rank test. Two-tailed P values were calculated,
with values below 0.05 considered to indicate statistical significance.
The quantitative angiographic results for 122 lesions treated
with stenting and 120 treated with angioplasty were analyzed by
multivariate analysis of variance with use of the BMDP program
4V.
 
29
 
 The results for individual lesions were not entirely inde-
pendent, since 18 percent of patients had multiple lesions. We
therefore used a linear-structure model of vessel measurements
that included a patient factor, which was tested under a second
“between” (or grouping) factor, treatment assignment (stenting
vs. angioplasty). In addition, the model contained a “within” (or
repeated-measures) factor, time (base line, immediately after the
procedure, or follow-up). The three dependent variables in the mul-
tivariate model were the diameter of the reference vessel, the mini-
mal luminal diameter, and the percentage of stenosis. Because the
term for the interaction of time and treatment assignment in the
model was significant for all three variables (P
 

 
0.002), the multi-
ple analysis of variance was performed for each level of the time
factor separately. Protection against the detection of spurious dif-
ferences due to multiple comparisons was afforded by the “pro-
tected F-tests” concept — that is, the principle of not interpreting
effects further when the overall F tests failed to reject the null hy-
pothesis.
 
30
 
RESULTS
 
Between January 1993 and June 1995, 220 pa-
tients were enrolled; 110 patients were assigned to
stent placement and 110 patients to angioplasty. Af-
ter randomization, five patients (two in the stent
group and three in the angioplasty group) were ex-
cluded because of violations of the protocol with re-
spect to enrollment criteria. The base-line clinical and
angiographic characteristics of the groups are shown
in Tables 1 and 2, respectively. The treated grafts were
relatively old: on average, 10.1 years in the stent
group and 9.4 years in the angioplasty group. The
groups were well matched except for a slightly higher
prevalence of diabetes in the angioplasty group.
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Procedural Outcomes
 
Stents were placed in 105 of 108 patients assigned
to this therapy (97 percent). Two patients assigned
to the stent group were treated with angioplasty be-
cause the characteristics of the lesions were deemed
unfavorable for stent placement at the time of the
procedure, and one patient underwent bypass sur-
gery. Balloon angioplasty was performed in 103 of
107 patients assigned to this therapy (96 percent).
Of the four patients assigned to angioplasty who did
not undergo the procedure, two were treated medi-
cally and two underwent bypass surgery. Seven pa-
tients in the angioplasty group (7 percent) required
bailout stent placement.
Rates of procedural success and early clinical out-
comes are shown in Table 3. Angiographic proce-
dural success was achieved in 97 percent of the pa-
tients assigned to stent placement and 86 percent of
those assigned to angioplasty (P
 

 
0.01). The rate of
procedural efficacy was also significantly higher in
the stent group than in the angioplasty group (92
percent vs. 69 percent, P
 

 
0.001). Thus, 31 percent
of patients assigned to angioplasty had an unsuccess-
ful angiographic result, had a major complication, or
required unplanned revascularization. In contrast,
only 8 percent of the stent group had an unsuccess-
ful angiographic result, a complication, or a need for
alternative therapy.
There were no significant differences between the
groups in terms of major in-hospital cardiac com-
plications. However, there was a trend toward fewer
non–Q-wave myocardial infarctions in the stent
group (2 percent, as compared with 7 percent in the
angioplasty group; P
 

 
0.10). Abrupt reclosure of
the vessel occurred in one patient in each group; the
incidence of thrombosis in the stented vessel within
one month was 0.9 percent. Bleeding and vascular
complications were significantly more common in
the stent group (17 percent vs. 5 percent, P
 

 
0.01).
 
Angiographic Results
 
Coronary angiography was repeated a mean (
 

 
SD)
of 6
 

 
2 months after the initial procedure in 166 of
193 patients eligible for angiographic follow-up (86
percent). The follow-up rate was similar for the
stent and angioplasty groups (88 percent and 84
percent, respectively; P not significant). The quan-
titative angiographic results are shown in Table 4.
Immediately after the intervention, a larger mean
gain in luminal diameter was achieved in the patients
assigned to stent placement (1.92
 

 
0.30 mm vs.
1.21
 

 
0.37 mm, P
 

 
0.001). Although the late loss
of luminal diameter was higher after stenting, there
was a significantly greater mean net gain in luminal
diameter at six months with stenting (0.85
 

 
0.96
mm vs. 0.54
 

 
0.91 mm, P
 

 
0.002). The minimal
luminal diameter at six months was 1.73
 

 
1.02 mm
 
*Plus–minus values are means 
 

 
SD. Five of the 220 patients originally
enrolled were excluded because of protocol violations.
†P
 

 
0.05 for the comparison between the groups.
 
T
 
ABLE
 
 1.
 
 B
 
ASE
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 C
 
LINICAL
 
 C
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OF
 
 
 
THE
 
 P
 
ATIENTS
 
.*
 
C
 
HARACTERISTIC
 
S
 
TENT
 
G
 
ROUP
 
(N
 

 
108)
A
 
NGIOPLASTY
 
 
G
 
ROUP
 
 
(N
 

 
107)
 
Age (yr) 66
 

 
9 66
 

 
9
Male sex (%) 82 79
Hyperlipidemia (%) 65 64
Hypertension (%) 61 55
Diabetes mellitus (%) 23 36†
Current smoking (%) 17 15
Prior myocardial infarction (%) 68 70
Myocardial infarction within 
previous 6 wk (%)
18 19
Unstable angina (%) 82 77
Ejection fraction 0.53
 

 
0.14 0.52
 

 
0.14
*Plus–minus values are means 
 

 
SD. There were no significant differenc-
es between the groups. Five of the 220 patients originally enrolled were
excluded because of protocol violations.
 
T
 
ABLE
 
 2.
 
 B
 
ASE
 
-L
 
INE
 
 A
 
NATOMICAL
 
 C
 
HARACTERISTICS
 
 
 
OF
 
 
 
THE
 
 P
 
ATIENTS
 
.*
 
C
 
HARACTERISTIC
 
S
 
TENT
 
G
 
ROUP
 
 
(N
 

 
108)
A
 
NGIOPLASTY
 
G
 
ROUP
(N107)
Age of graft (yr)
Recipient native vessel (%)
Left anterior descending artery
Left circumflex artery
Right coronary artery
Multiple
10.14.2
33
31
28
8
9.44.3
36
29
27
8
Distal anastomosis (%)
Single
Multiple
84
16
82
18
Location of target lesion (%)
Aortic anastomosis
Proximal third
Middle third
Distal third
Coronary anastomosis
7
43
29
19
2
9
29
36
21
5
No. of lesions treated (%)
1
2
3
82
14
4
83
10
7
Length of lesion (mm)
Degree of stenosis (% of diameter)
Eccentricity (%)
Ulceration (%)
Thrombus (%)
Definite
Possible
Lesion on bend 45 degrees (%)
Tortuous graft (%)
9.65.4
7212
73
35
6
18
11
39
9.85.2
7112
82
39
8
22
10
39
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*Plus–minus values are means SD. CABG denotes coronary-artery bypass graft surgery, and
PTCA percutaneous transluminal coronary angioplasty. Five of the 220 patients originally enrolled
were excluded because of protocol violations.
†Angiographic success was defined as residual stenosis of less than 50 percent of the vessel diameter
immediately after the procedure. Efficacy was defined as angiographic success achieved with the as-
signed therapy and the absence of a major in-hospital complication.
TABLE 3. PROCEDURAL OUTCOMES AND EARLY CLINICAL EVENTS.*
VARIABLE
STENT
GROUP 
(N108)
ANGIOPLASTY
GROUP (N107) P VALUE
Procedural outcome†
Angiographic success (%)
Procedural efficacy (%)
Crossover to stenting (%)
Hospital stay (days)
97
92
—
76
86
69
7
47
0.01
0.001
—
0.001
In-hospital events (%)
Death 
Q-wave myocardial infarction 
Non–Q-wave myocardial infarction 
CABG 
Abrupt vessel closure 
Repeated PTCA 
Any event 
2
2
2
2
1
1
6
2
1
7
4
1
1
11
0.79
0.99
0.10
0.45
0.99
0.99
0.13
Bleeding and vascular complications at
0–30 days (%)
Stroke 
Vascular surgery 
Transfusion 
Any event 
0
5
15
17
0
3
3
5
0.99
0.72
0.01
0.01
*Plus–minus values are means SD. The results are means for all lesions, unless otherwise speci-
fied. In the stent group, 122 lesions were treated in 108 patients; in the angioplasty group, 120 le-
sions in 107 patients.
TABLE 4. CHARACTERISTICS OF LESIONS AT BASE LINE AND ANGIOGRAPHIC RESULTS 
IMMEDIATELY AFTER THE PROCEDURE AND AT SIX MONTHS.*
VARIABLE STENT GROUP
ANGIOPLASTY
GROUP P VALUE
At base line
Diameter of reference vessel — mm
Minimal luminal diameter — mm
Degree of stenosis — % of diameter
3.180.56
0.900.42
7212
3.190.61
0.940.44
7112
0.36
0.34
0.47
After procedure
Diameter of reference vessel — mm
Minimal luminal diameter — mm
Degree of stenosis — % of diameter
Elastic recoil — %
Dissection — % of lesions
3.190.55
2.810.49
1213
139
7
3.190.61
2.160.57
3217
3016
29
0.55
0.001
0.001
0.001
0.001
At 6 mo 
Diameter of reference vessel — mm
Minimal luminal diameter — mm
Degree of stenosis — % of diameter
Restenosis in lesion — no./total no. (%)
Restenosis in patient — no./total no. (%)
3.140.54
1.731.02
4630
35/98 (36)
32/86 (37)
3.110.57
1.490.88
5126
43/91 (47)
37/80 (46)
0.95
0.01
0.02
0.11
0.24
Change in minimal luminal diameter — mm
Immediate gain 
Late loss 
Net gain 
1.920.30
1.060.92
0.850.96
1.210.37
0.660.87
0.540.91
0.001
0.001
0.002
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in the stent group and 1.490.88 mm in the angio-
plasty group (P0.01). Cumulative frequency dis-
tributions of minimal luminal diameters in the two
groups are shown in Figure 1.
When the results were analyzed according to
intention-to-treat principles, restenosis was found in
37 percent of the patients in the stent group and
in 46 percent of the patients in the angioplasty
group (P0.24). The relative risk of restenosis in a
patient after stenting was 0.84 (95 percent confi-
dence interval, 0.64 to 1.11); after adjustment for
diabetes mellitus, the relative risk was 0.83 (95 per-
cent confidence interval, 0.63 to 1.08). Restenosis
was observed in 36 percent of the lesions in the
stent group and in 47 percent of the lesions in the
angioplasty group (P0.11). The relative risk of re-
stenosis in a lesion after stenting was 0.82 (95 per-
cent confidence interval, 0.64 to 1.05); after adjust-
ment for diabetes, the relative risk was 0.83 (95
percent confidence interval, 0.64 to 1.06). When
only patients who received the assigned therapy ac-
cording to the protocol were analyzed, the differ-
ences in the rates of restenosis were statistically sig-
nificant: 34 percent for the patients treated with
stenting as compared with 48 percent for those
treated with angioplasty (P0.05). The relative risk
of restenosis was 0.77 (95 percent confidence inter-
val, 0.60 to 0.99) for the stent group as compared
with the angioplasty group; after adjustment for di-
abetes, the relative risk was 0.78 (95 percent confi-
dence interval, 0.60 to 1.01).
Late Clinical Events
The cumulative incidence of major cardiac events
at follow-up is shown in Table 5. The rate of event-
free survival (freedom from death, myocardial infarc-
tion, repeated bypass surgery, and revascularization
of the target lesion) was significantly greater for pa-
tients assigned to stenting than for patients assigned
to balloon angioplasty (Fig. 2). At 240 days, the rate
of event-free survival by Kaplan–Meier analysis was
73 percent in the stent group as compared with 58
percent in the angioplasty group (P0.03). The rel-
ative risk of a major cardiac event associated with
stenting was 0.82 (95 percent confidence interval,
0.68 to 0.98); after adjustment for diabetes, the rel-
ative risk was 0.82 (95 percent confidence interval,
0.68 to 0.99).
DISCUSSION
Recurrent myocardial ischemia after coronary-
artery bypass surgery is a common clinical problem
because of the large number of patients with bypass
grafts implanted many years earlier. Angiographic
studies have found that within 10 years after the op-
eration, half of all vein grafts are totally occluded or
have severe atherosclerotic disease.1-7 Repeated bypass
surgery is more technically challenging than a first op-
eration, is associated with higher morbidity and mor-
tality, and provides less symptomatic relief.8-11 An-
gioplasty is therefore often attempted in lieu of
reoperation. However, the results of balloon angio-
plasty in saphenous-vein bypass grafts are less favor-
Figure 1. Cumulative Distribution of Minimal Luminal Diame-
ters in the Treatment Groups at Base Line, Immediately after
the Procedure, and at Six Months.
The degree of initial luminal narrowing was similar in the two
treatment groups, as demonstrated by the near-superimposi-
tion of the curves at base line. The curves separate after the
procedure and at follow-up, indicating the larger luminal diam-
eter achieved by stent placement.
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TABLE 5. MAJOR CARDIAC EVENTS UP TO 240 DAYS AFTER THE PROCEDURE.
EVENT
STENT
GROUP 
(N108)
ANGIOPLASTY
GROUP 
(N107) P VALUE
percent
Death 
Q-wave myocardial infarction
Non–Q-wave myocardial infarction
Coronary bypass surgery
Repeated angioplasty
Target-lesion revascularization
7
5
6
7
13
17
9
4
11
12
16
26
0.44
0.99
0.13
0.24
0.54
0.09
Any event 26 39 0.04
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able than those in native vessels, with rates of reste-
nosis exceeding 50 percent.12-16 Furthermore, the
rates of complications and restenosis increase once
the age of a graft exceeds three to five years.13,15,16
Given the limitations of these therapies, stent im-
plantation has been suggested as an alternative ther-
apeutic approach. Observational studies of patients
who have received the Palmaz–Schatz stent have re-
ported relatively low rates of restenosis.19-22 However,
there have been no direct comparisons of angioplas-
ty and stent implantation for the treatment of dis-
ease in saphenous-vein grafts.
The results of our randomized trial demonstrate
that elective stent placement produces better angio-
graphic and clinical outcomes than balloon angioplas-
ty in the treatment of new lesions in aortocoronary
venous bypass grafts. Stenting was associated with
superior initial angiographic results, higher rates of
procedural success, and a trend toward fewer peripro-
cedural non–Q-wave myocardial infarctions. Although
the rates of restenosis were not significantly different
with the two treatment strategies, at six months the
luminal diameter was significantly larger in the stent
group. Most important, clinical outcome was im-
proved by stenting. The proportion of patients who
were free from death, myocardial infarction, repeated
bypass surgery, and revascularization of the target le-
sion was significantly greater in the stent group.
The findings of this study are concordant with
those of the Stent Restenosis Study (STRESS) and
the Belgium–Netherlands Stent (Benestent) trial,
which found superior outcomes with stenting in na-
tive coronary arteries.17,18 On the other hand, our
findings contrast with data on directional atherecto-
my in bypass-graft lesions reported by the second
Coronary Angioplasty versus Excisional Atherecto-
my Trial (CAVEAT II).31,32 Although both stenting
and atherectomy produced better initial angiograph-
ic results in vein grafts than angioplasty, atherectomy
was associated with more procedural complications,
particularly distal embolization.31,32 The trend to-
ward more non–Q-wave infarctions in patients treat-
ed with atherectomy contrasts with the trend toward
fewer non–Q-wave infarctions in patients treated
with stenting in our trial. Possibly the screen-like
configuration of the stent may entrap friable graft
atheroma, thereby reducing the likelihood of dis-
lodgement and embolization of larger debris.
Several limitations of stenting should be empha-
sized. The intense anticoagulation protocol used in
this trial resulted in a significant increase in hemor-
rhagic complications. Similar findings were observed
in the Benestent and STRESS trials, which used sim-
ilar anticoagulant regimens.17,18 Although this pro-
tocol was standard therapy when the trial was per-
formed, subsequent studies have shown the superior
safety and efficacy of aspirin and ticlopidine in con-
junction with high-pressure stent deployment.33-35 A
reduction in the rate of hemorrhagic complications
after vein-graft stenting has also been reported with
antiplatelet therapy alone.36
The results of this study cannot be extrapolated to
populations excluded from the trial, such as patients
with restenotic or diffusely diseased grafts. In a pro-
spective study of Palmaz–Schatz stents in vein-graft
disease, we found a significantly higher rate of reste-
nosis of single stents placed in recurrent lesions than
of those placed in new lesions (51 percent vs. 22
percent).20
It is important to emphasize limitations due to the
open nature of this trial, since patients and operators
were not blinded to the treatment. Thus, the possibil-
ity of bias cannot be excluded despite the prospective,
randomized trial design. This caveat is pertinent not
only to the angiographic results but also to clinical
end points, since the decision to perform additional
procedures could have been influenced by the knowl-
edge that the stent was present. On the other hand,
several factors support our findings. First, quantitative
measurements of the severity of stenosis were per-
formed by a core laboratory using a validated com-
puterized program that automatically determined the
luminal dimensions. Second, the results of this trial of
stenting in vein grafts closely corroborate the findings
of the two landmark trials of stents in native ves-
sels.17,18 In all three studies, stent placement was asso-
ciated with a larger gain in minimal luminal diameter,
a reduction of 25 to 30 percent in the risk of reste-
nosis, and fewer cardiac events. Finally, in this trial
knowledge of the patients’ treatment assignment did
not appear to influence the use of further procedures
Figure 2. Kaplan–Meier Survival Curves for Freedom from Ma-
jor Cardiac Events.
The rate of event-free survival was significantly higher among
patients assigned to stenting than among those assigned to
angioplasty. The relative risk of a major cardiac event after
stenting was 0.82 (95 percent confidence interval, 0.68 to 0.98);
after adjustment for diabetes, the relative risk was 0.82 (95 per-
cent confidence interval, 0.68 to 0.99).
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to treat restenosis. In patients with angiographic ev-
idence of restenosis, the proportion of patients un-
dergoing revascularization of the target lesion was
virtually identical in the two study groups: 59 per-
cent after stenting and 58 percent after angioplasty.
A final limitation of this study is that stenting was
less effective in reducing the rate of restenosis than
we anticipated. With respect to a priori assumptions,
the rate of restenosis in the balloon angioplasty group
was lower than expected, whereas the rate of reste-
nosis in the stent group was higher than expect-
ed.12-16,22,31 According to quantitative coronary anal-
ysis by the same core angiographic laboratory used
in this study, restenosis in the multicenter registry of
vein-graft stenting was only 22 percent,20 a rate sub-
stantially lower than that in the current trial. A sim-
ilar phenomenon was observed in the STRESS trial,
in which there was a significant discordance in rates
of restenosis between the registry and randomized
studies. The rate of restenosis of stented vessels in na-
tive coronary arteries was 32 percent in the prospec-
tive randomized trial, as compared with only 14 per-
cent in the registry, despite similar inclusion criteria
and analysis by the same core laboratory.18,28 These
results suggest a bias toward favorable outcomes in
observational registries of the use of interventional
devices. As a result, the use of the intention-to-treat
principle in a prospective, randomized trial may yield
results that are less favorable than expected.
As compared with conventional angioplasty, stent
placement in new vein-graft lesions was associated
with better initial angiographic results and higher
rates of procedural success. Although the luminal di-
ameter at six months was larger in the stent group,
there was no significant difference in the rate of re-
stenosis, the primary angiographic end point. How-
ever, major cardiac events occurred less frequently in
the stent group. Continued follow-up is planned to
assess longer-term clinical outcomes.
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APPENDIX
The following institutions and investigators, in addition to the authors,
participated in the Saphenous Vein De Novo (SAVED) trial: Arizona Heart
Institute, Phoenix; Emory University Hospital, Atlanta; Johns Hopkins
Hospital, Baltimore; Methodist Hospital, Lubbock, Tex.; the Heart Group,
Bellevue, Wash.; Thomas Jefferson University Hospital, Philadelphia —
A. Zalewski and P. Walinsky; University of California, San Diego, La Jolla;
University of Florida, Gainesville — R. Kerensky and T. Wargovich; Uni-
versity of Texas, Houston; University of Texas, San Antonio — S.R. Kiesz;
William Beaumont Hospital, Royal Oak, Mich.; Yale University, New Ha-
ven, Conn. — H. Cabin; Beth Israel Deaconess Medical Center, Boston —
D. Baim; Core Angiographic Laboratory, Thomas Jefferson University
Hospital, Philadelphia — D. Rehmann; and Data Coordinating Center,
Johnson & Johnson Interventional Systems, Warren, N.J. — J. Gwo,
J. Lind, and C. Ray.
REFERENCES
1. Lawrie GM, Lie JT, Morris GC Jr, Beazley HL. Vein graft patency and 
intimal proliferation after aortocoronary bypass: early and long-term angio-
pathologic correlations. Am J Cardiol 1976;38:856-62.
2. Hamby RI, Aintablian A, Handler M, et al. Aortocoronary saphenous 
vein bypass grafts: long-term patency, morphology and blood flow in pa-
tients with patent grafts early after surgery. Circulation 1979;60:901-9.
3. Bourassa MG, Enjalbert M, Campeau L, Lesperance J. Progression of 
atherosclerosis in coronary arteries and bypass grafts: ten years later. Am
J Cardiol 1984;53:102C-107C.
4. Bourassa MG, Fisher LD, Campeau L, Gillespie MJ, McConney M, 
Lesperance J. Long-term fate of bypass grafts: the Coronary Artery Surgery 
Study (CASS) and Montreal Heart Institute experiences. Circulation 1985;
72:Suppl V:V-71–V-78.
5. Virmani R, Atkinson JB, Forman MB. Aortocoronary saphenous vein 
bypass grafts. Cardiovasc Clin 1988;18:41-62.
6. Lytle BW, Loop FD, Cosgrove DM, Ratliff NB, Easley K, Taylor PC. 
Long-term (5 to 12 years) serial studies of internal mammary artery and 
saphenous vein coronary bypass grafts. J Thorac Cardiovasc Surg 1985;89:
248-58.
7. FitzGibbon GM, Leach AJ, Kafka HP, Keon WJ. Coronary bypass 
graft fate: long-term angiographic study. J Am Coll Cardiol 1991;17:1075-
80.
8. Schaff HV, Orszulak TZ, Gersh BJ, et al. The morbidity and mortality 
of reoperation for coronary artery disease and analysis of late results with 
use of actuarial estimate of event-free interval. J Thorac Cardiovasc Surg 
1983;85:508-15.
9. Loop FD, Cosgrove DM. Repeat coronary bypass surgery: selection of 
cases, surgical risks, and long-term outlook. Mod Concepts Cardiovasc Dis 
1986;55:31-6.
10. Laird-Meeter K, van Domburg R, van den Brand MJ, Lubsen J, Bos 
E, Hugenholtz PG. Incidence, risk and outcome of reintervention after 
aortocoronary bypass surgery. Br Heart J 1987;57:427-35.
11. Cameron A, Kemp HG Jr, Green GE. Reoperation for coronary artery 
disease: 18 years of clinical follow-up. Circulation 1988;78:Suppl I:I-158–
I-162.
12. de Feyter PJ, van Suylen R-J, de Jaegere PPT, Topol EJ, Serruys PW. 
Balloon angioplasty for the treatment of lesions in saphenous vein bypass 
grafts. J Am Coll Cardiol 1993;21:1539-49.
13. Douglas JS Jr, Gruentzig AR, King SB III, et al. Percutaneous trans-
luminal coronary angioplasty in patients with prior coronary bypass sur-
gery. J Am Coll Cardiol 1983;2:745-54.
14. Dorros G, Johnson WD, Tector AJ, Schmahl TM, Kalush SL, Janke L. 
Percutaneous transluminal coronary angioplasty in patients with prior cor-
onary artery bypass grafting. J Thorac Cardiovasc Surg 1984;87:17-26.
15. Platko WP, Hollman J, Whitlow PL, Franco I. Percutaneous translu-
minal angioplasty of saphenous vein graft stenosis: long-term follow-up.
J Am Coll Cardiol 1989;14:1645-50.
16. Reeves F, Bonan R, Cote H, et al. Long-term angiographic follow-up 
angioplasty of venous coronary bypass grafts. Am Heart J 1991;122:620-
7.
17. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-
expandable–stent implantation with balloon angioplasty in patients with 
coronary artery disease. N Engl J Med 1994;331:489-95.
18. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison 
of coronary-stent placement and balloon angioplasty in the treatment of 
coronary artery disease. N Engl J Med 1994;331:496-501.
19. Strumpf RK, Mehta SS, Ponder R, Heuser RR. Palmaz-Schatz stent 
implantation in stenosed saphenous vein grafts: clinical and angiographic 
follow-up. Am Heart J 1992;123:1329-36.
20. Fenton SH, Fischman DL, Savage MP, et al. Long-term angiographic 
and clinical outcome after implantation of balloon-expandable stents in 
aortocoronary saphenous vein grafts. Am J Cardiol 1994;74:1187-91.
21. Piana RN, Moscucci M, Cohen DJ, et al. Palmaz-Schatz stenting for 
treatment of focal vein graft stenosis: immediate results and long-term out-
come. J Am Coll Cardiol 1994;23:1296-304.
22. Wong SC, Baim DS, Schatz RA, et al. Immediate results and late out-
comes after stent implantation in saphenous vein graft lesions: the multi-
center U.S. Palmaz-Schatz stent experience. J Am Coll Cardiol 1995;26:
704-12.
23. Schatz RA, Baim DS, Leon M, et al. Clinical experience with the Pal-
maz-Schatz coronary stent: initial results of a multicenter study. Circula-
tion 1991;83:148-61.
24. Fischman DL, Savage MP, Ellis S, et al. The Palmaz-Schatz stent. In: 
Reiber JHC, Serruys PW, eds. Advances in quantitative coronary arteriog-
raphy. Vol. 137 of Developments in cardiovascular medicine. Dordrecht, 
the Netherlands: Kluwer Academic, 1993:553-66.
25. Ellis SG, Savage M, Fischman D, et al. Restenosis after placement of 
Palmaz-Schatz stents in native coronary arteries: initial results of a multi-
center experience. Circulation 1992;86:1836-44.
The New England Journal of Medicine 
Downloaded from nejm.org at THOMAS JEFFERSON UNIVERSITY on March 7, 2012. For personal use only. No other uses without permission. 
 Copyright © 1997 Massachusetts Medical Society. All rights reserved. 
STENT PLACEMENT VS. BALLOON ANGIOPLASTY FOR OBSTRUCTED CORONARY BYPASS GRAFTS
Volume 337 Number 11  747
26. Mancini GBJ, Simon SB, McGillem MJ, LeFree MT, Friedman HZ, 
Vogel RA. Automated quantitative coronary arteriography: morphologic 
and physiologic validation in vivo of a rapid digital angiographic method. 
Circulation 1987;75:452-60. [Erratum, Circulation 1987;75:1199.]
27. Fischman DL, Savage MP, Leon MB, et al. Effect of intracoronary 
stenting on intimal dissection after balloon angioplasty: results of quanti-
tative and qualitative coronary analysis. J Am Coll Cardiol 1991;18:1445-
51.
28. Savage MP, Fischman DL, Schatz RA, et al. Long-term angiographic 
and clinical outcome after implantation of a balloon-expandable stent in 
the native coronary circulation. J Am Coll Cardiol 1994;24:1207-12.
29. Dixon WJ, ed. BMDP statistical software. Release 7. Vol. 2. Berkeley: 
University of California Press, 1992:1259-310.
30. Bock RD. Multivariate statistical methods in behavioral research. New 
York: McGraw-Hill, 1975:266-8, 422-4.
31. Holmes DR Jr, Topol EJ, Califf RM, et al. A multicenter, randomized 
trial of coronary angioplasty versus directional atherectomy for patients 
with saphenous vein bypass graft lesions. Circulation 1995;91:1966-
74.
32. Lefkovits J, Holmes DR, Califf RM, et al. Predictors and sequelae of 
distal embolization during saphenous vein graft intervention from the 
CAVEAT-II trial. Circulation 1995;92:734-40.
33. Colombo A, Hall P, Nakamura S, et al. Intracoronary stenting without 
anticoagulation accomplished with intravascular ultrasound guidance. Cir-
culation 1995;91:1676-88.
34. Morice MC, Zemour G, Benveniste E, et al. Intracoronary stenting 
without Coumadin: one month results of a French multicenter study. 
Cathet Cardiovasc Diagn 1995;35:1-7.
35. Schömig A, Neumann F-J, Kastrati A, et al. A randomized comparison 
of antiplatelet and anticoagulant therapy after the placement of coronary-
artery stents. N Engl J Med 1996;334:1084-9.
36. Leon MB, Ellis SG, Moses J, et al. Interim report from the Reduced 
Anticoagulation Vein Graft Stent (RAVES) study. Circulation 1996;94:
Suppl:I-683. abstract.
Northern New Mexico LUCY FOX, M.D.
The New England Journal of Medicine 
Downloaded from nejm.org at THOMAS JEFFERSON UNIVERSITY on March 7, 2012. For personal use only. No other uses without permission. 
 Copyright © 1997 Massachusetts Medical Society. All rights reserved. 
